Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study

Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study

Talazoparib (Talzenna) is a novel poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor that is clinically used for the therapy of breast cancer. Furthermore, the drug has shown antitumor activity against different cancer types, including non-small cell lung cancer (NSCLC). In this work, w...

Full description

Bibliographic Details
Main Authors:	Ziba Sabet, Dimitrios Vagiannis, Youssif Budagaga, Yu Zhang, Eva Novotná, Ivo Hanke, Tomáš Rozkoš, Jakub Hofman
Format:	Article
Language:	English
Published:	MDPI AG 2022-11-01
Series:	International Journal of Molecular Sciences
Subjects:	talazoparib ABC transporter small cell lung cancer multidrug resistance pharmacokinetic drug–drug interaction cytochrome P450
Online Access:	https://www.mdpi.com/1422-0067/23/22/14338

Similar Items

Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method
by: Zahra Talebi, et al.
Published: (2023-11-01)

Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo
by: Yu Zhang, et al.
Published: (2022-11-01)

Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme
by: Dimitrios Vagiannis, et al.
Published: (2020-03-01)

Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo
by: Dimitrios Vagiannis, et al.
Published: (2021-11-01)

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents
by: Dong Zhou, et al.
Published: (2021-05-01)

Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
by: Paige Baldwin, et al.
Published: (2019-12-01)

A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)
by: Ticiana A. Leal, et al.
Published: (2022-11-01)

Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
by: Florian G. Klein, et al.
Published: (2021-04-01)

Comparison between talazoparib and conventional chemotherapy in the treatment of HER2-positive breast cancer patients: A retrospective study
by: Ning Wang, et al.
Published: (2022-08-01)

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib
by: Jiaguo Li, et al.
Published: (2020-01-01)

Combination of Talazoparib and Calcitriol Enhanced Anticancer Effect in Triple−Negative Breast Cancer Cell Lines
by: Fu Hou Wong, et al.
Published: (2022-08-01)

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature
by: Víctor Albarrán, et al.
Published: (2023-05-01)

Case Report: Progressive disease of BRCA2-mutant colon adenocarcinoma following talazoparib therapy
by: Elizaveta Polyanskaya, et al.
Published: (2023-11-01)

Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review
by: Andrei Kachmazov, et al.
Published: (2022-09-01)

Karanjin interferes with ABCB1, ABCC1, and ABCG2
by: Martin Michaelis, et al.
Published: (2014-03-01)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
by: Shicheng Yang, et al.
Published: (2023-05-01)

A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer
by: Paige Baldwin, et al.
Published: (2024-03-01)

Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells
by: Chung-Pu Wu, et al.
Published: (2023-09-01)

PARP inhibitors in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. Experience of treatment with talazoparib in clinical practice
by: M. A. Frolova, et al.
Published: (2020-07-01)

Russian multicenter experience of using talazoparib in the treatment of patients with BRCA-associated metastatic breast cancer
by: T. Yu. Semiglazova, et al.
Published: (2020-12-01)

Intrinsic and Chemotherapeutic Stressors Modulate ABCC-Like Transport in <i>Trypanosoma cruzi</i>
by: Kelli Monteiro da Costa, et al.
Published: (2021-06-01)

Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer
by: Jihui Chen, et al.
Published: (2021-02-01)

Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies
by: Vanessa Kohl, et al.
Published: (2019-10-01)

Extracellular Vesicles as Surrogates for the Regulation of the Drug Transporters ABCC2 (MRP2) and ABCG2 (BCRP)
by: Juan Pablo Rigalli, et al.
Published: (2024-04-01)

CORRELATION BETWEEN CHEMOTHERAPY RESPONSE AND EXPRESSION PROFILES OF TRANSMEMBRANE PROTEINS: P-GLYCOPROTEIN (ABCB1), MRP2 (ABCC2), BCRP (ABCG2) IN PATIENTS WITH INVASIVE BREAST CANCER
by: К. Yu. Khristenko, et al.
Published: (2016-10-01)

Structure of ABCB1/P-Glycoprotein in the Presence of the CFTR Potentiator Ivacaftor
by: Alessandro Barbieri, et al.
Published: (2021-11-01)

Differential Action of Silver Nanoparticles on ABCB1 (MDR1) and ABCC1 (MRP1) Activity in Mammalian Cell Lines
by: Damian Krzyzanowski, et al.
Published: (2021-06-01)

Intronic polymorphisms of cytochromes P450
by: Ingelman-Sundberg Magnus, et al.
Published: (2010-08-01)

In Vitro Assessment of the Effect of Antiepileptic Drugs on Expression and Function of ABC Transporters and Their Interactions with ABCC2
by: Gurpreet Kaur Grewal, et al.
Published: (2017-09-01)

ABCG2/BCRP transport mechanism revealed through kinetically excited targeted molecular dynamics simulations
by: B. Dudas, et al.
Published: (2022-01-01)

Novel ABCB1 and ABCC Transporters Are Involved in the Detoxification of Benzo(α)pyrene in Thick Shell Mussel, Mytilus coruscus
by: Baoying Guo, et al.
Published: (2020-03-01)

Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature
by: Louisa Taylor, et al.
Published: (2023-02-01)

ABCB1 and ABCC1 Function during TGF-β-Induced Epithelial-Mesenchymal Transition: Relationship between Multidrug Resistance and Tumor Progression
by: Kelli Monteiro da Costa, et al.
Published: (2023-03-01)

Cellular Processing of the ABCG2 Transporter—Potential Effects on Gout and Drug Metabolism
by: Orsolya Mózner, et al.
Published: (2019-10-01)

ABCG5 and ABCG8 Are Involved in Vitamin K Transport
by: Michinori Matsuo, et al.
Published: (2023-02-01)

Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo
by: Yiran Wang, et al.
Published: (2020-02-01)

Use of drugs that act on the cytochrome P450 system in the elderly
by: Marcos A. S. Cabrera, et al.
Published: (2009-04-01)

Targeting autophagy potentiates the anti-tumor effect of PARP inhibitor in pediatric chronic myeloid leukemia
by: Yuanyuan Liu, et al.
Published: (2019-07-01)

Residues from Homologous Transmembrane Helices 4 and 10 Are Critical for P-Glycoprotein (ABCB1)-Mediated Drug Transport
by: Hadiar Rahman, et al.
Published: (2023-07-01)

New ABCC2 rs3740066 and rs2273697 Polymorphisms Identified in a Healthy Colombian Cohort
by: Rosa Helena Bustos-Cruz, et al.
Published: (2018-07-01)